Increased PD-L1 expression in breast and colon cancer stem cells

被引:93
|
作者
Wu, Yanheng [1 ]
Chen, Mingshui [1 ,2 ,3 ]
Wu, Peihong [4 ,5 ]
Chen, Chen [6 ]
Xu, Zhi Ping [1 ]
Gu, Wenyi [1 ]
机构
[1] Univ Queensland, Australian Inst Bioengn & Nanotechnol, Bldg 75,Cooper Rd, Brisbane, Qld 4072, Australia
[2] Fujian Prov Canc Hosp & Inst, Lab Immunooncol, Dept Med Oncol, Fuzhou, Peoples R China
[3] Fujian Prov Key Lab Translat Canc Med, Fuzhou, Peoples R China
[4] Sun Yat Sen Univ, Dept Med Imaging & Intervent Radiol, Ctr Canc, Guangzhou, Guangdong, Peoples R China
[5] Sun Yat Sen Univ, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China
[6] Univ Queensland, Sch Biomed Sci, Brisbane, Qld, Australia
关键词
CLINICAL-SIGNIFICANCE; SELF-RENEWAL; PATHWAY; SAFETY;
D O I
10.1111/1440-1681.12732
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Here we report the expression of programmed cell death ligand 1/2 (PD-L1/L2) in breast and colon cancer stem cells (CSCs). The stemness of these cells was confirmed by their surface markers. Using flow cytometry analysis we demonstrated that PD-L1 expression was higher in CSCs of both cancers compared to non-stem like cancer cells. Consistent with this, detection of cellular PD-L1 proteins by western blot assay also showed increased PD-L1 protein in CSCs. In contrast, only trace amounts of PD-L2 were detected in CSCs of both cancers. Our results suggest that breast and colon cancers may be sensitive to PD1/PD-L1 immunotherapy and thus warrant further investigations of CSC targeted PD1/PD-L1 therapy.
引用
收藏
页码:602 / 604
页数:3
相关论文
共 50 条
  • [41] The effect of cardamonin on PD-L1 expression in triple-negative breast cancer cells
    Mendonca, Patricia
    Kirpal, Bhonessa
    Kaur, Sukhmandeep
    Soliman, Karam F. A.
    CANCER RESEARCH, 2024, 84 (06)
  • [42] PD-1/PD-L1 Expression in Brain Metastases from Breast Cancer
    Gawelek, Kara
    Williams, Nicole
    Varadan, Vinay
    Harris, Lyndsay
    Gilmore, Hannah
    LABORATORY INVESTIGATION, 2016, 96 : 42A - 42A
  • [43] PD-1/PD-L1 Expression in Brain Metastases from Breast Cancer
    Gawelek, Kara
    Williams, Nicole
    Varadan, Vinay
    Harris, Lyndsay
    Gilmore, Hannah
    MODERN PATHOLOGY, 2016, 29 : 42A - 42A
  • [44] The prognostic value of PD-L1/PD-1 expression and PD-L1 gene copy number on/in tumor and immune cells in triple negative breast cancer
    Seitz, S.
    Brockhoff, G.
    Weber, F.
    Klinkhammer-Schalke, M.
    Zeman, F.
    Ugocsai, P.
    Ortmann, O.
    Wege, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 4 - 4
  • [45] PD-L1 is overexpressed on tumorspheres cultured from circulating cancer stem cells in patients with breast cancer
    Pizon, Monika
    Schott, Dorothea
    Pachmann, Ulrich A.
    Pizon, Marek
    Pachmann, Katharina
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Regulation of PD-L1 in breast cancer
    Zerdes, Ioannis
    Tsesmetzis, Nikolaos
    Lovrot, John
    Rolny, Charlotte
    Bergh, Jonas C. S.
    Rassidakis, Georgios
    Foukakis, Theodoros
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [47] PD-L1 testing in breast cancer
    Horii, Rie
    ANNALS OF ONCOLOGY, 2023, 34 : S1361 - S1361
  • [48] Increased expression of TAZ and associated upregulation of PD-L1 in cervical cancer
    Yanyan Han
    Dandan Liu
    Lianhong Li
    Cancer Cell International, 21
  • [49] Increased expression of TAZ and associated upregulation of PD-L1 in cervical cancer
    Han, Yanyan
    Liu, Dandan
    Li, Lianhong
    CANCER CELL INTERNATIONAL, 2021, 21 (01)
  • [50] Mesenchymal Stem Cells Upregulate the Expression of PD-L1 But Not VDR in Dendritic Cells
    Moravej, Ali
    Karimi, Mohammad-Hossein
    Geramizadeh, Bita
    Azarpira, Negar
    Zarnani, Amir-Hasan
    Yaghobi, Ramin
    Khosravi, Maryam
    Kalani, Mehdi
    Gharesi-Fard, Behrouz
    IMMUNOLOGICAL INVESTIGATIONS, 2017, 46 (01) : 80 - 96